The thing is, a lot of retail morons (aka The Kramer and Cramer crowd), don't know how to look at the data and panic. Personally, I think the OS data which we have already seen (2 months survival +) is fine enough to show that the drug has a clinical benefit.
I'm sure there were a lot of morons out there that were expecting the data to show 12 months or something...which it probably will in the people it works best in (which is unfortunate they still don't have a proper biomarker for those patients)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.